NCT06927791 MAchine Learning to Boost the Early Diagnosis of Acute Cardiovascular Conditions
| NCT ID | NCT06927791 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Acute Cardiovascular Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200,000 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200,000 participants in total. It began in 2024-04-01 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The research project aims to develop clinical decision support tools integrating established diagnostic variables and machine learning (ML) models for rapid diagnosis of acute life-threatening cardiovascular conditions in emergency department (ED) patients with chest pain or dyspnea with the ultimate goal of Improved diagnostic accuracy, faster patient management, and reduced medical errors.
Eligibility Criteria
Inclusion Criteria: • Acute cardiovascular disease (ACVD) Exclusion Criteria * age \< 18 years old * patients presenting in cardiogenic shock * chronic terminal kidney failure requiring dialysis
Contact & Investigator
Christian Müller, Prof. Dr. med.
STUDY DIRECTOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT06927791 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Cardiovascular Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06927791 currently recruiting?
Yes, NCT06927791 is actively recruiting participants. Contact the research team at jasper.boeddinghaus@usb.ch for enrollment information.
Where is the NCT06927791 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT06927791 clinical trial?
NCT06927791 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Christian Müller, Prof. Dr. med. at University Hospital, Basel, Switzerland. The trial plans to enroll 200,000 participants.